Advertisement
Screener

OMEROS CORP (OMER) Revenues

2.8 / 5 stars · 68/120 Roast Me

OMEROS CORP Revenues

OMEROS CORP (OMER) reported Revenues of $21.78 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.

Discontinued › Income Statement

us-gaap:Revenues · last filed 2019-05-09

  • OMEROS CORP revenues for the quarter ending 2019-03-31 was $21.78M, a 1271.47% increase year-over-year.
  • OMEROS CORP revenues for the quarter ending 2018-12-31 was $22.02M, a 60.01% increase year-over-year.
  • OMEROS CORP revenues for the quarter ending 2018-09-30 was $4.61M, a 78.72% decline year-over-year.
  • OMEROS CORP revenues for the quarter ending 2018-06-30 was $1.66M, a 90.35% decline year-over-year.
  • OMEROS CORP revenues for fiscal 2018 was $29.87M, a 53.93% decline from fiscal 2017.
  • OMEROS CORP revenues for fiscal 2017 was $64.83M, a 55.77% increase from fiscal 2016.
  • OMEROS CORP revenues for fiscal 2016 was $41.62M, a 208.07% increase from fiscal 2015.
  • OMEROS CORP revenues for fiscal 2015 was $13.51M, a 2406.31% increase from fiscal 2014.
Period endRevenues 3 monthRevenues 6 monthRevenues 9 monthRevenues 12 monthRevenues 204 monthRevenues 207 month
2019-03-31$21.78M
10-Q · filed 2019-05-09
$43.80M
derived: sum of 2 quarters · filed 2019-05-09
$48.40M
derived: sum of 3 quarters · filed 2019-05-09
$50.06M
derived: sum of 4 quarters · filed 2019-05-09
2018-12-31$22.02M
10-K · filed 2019-03-01
$26.63M
derived: sum of 2 quarters · filed 2019-03-01
$28.28M
derived: sum of 3 quarters · filed 2019-03-01
$29.87M
10-K · filed 2019-03-01
2018-09-30$4.61M
10-K · filed 2019-03-01
$6.26M
derived: sum of 2 quarters · filed 2019-03-01
$7.85M
10-Q · filed 2018-11-08
$21.61M
derived: sum of 4 quarters · filed 2019-05-09
2018-06-30$1.66M
10-K · filed 2019-03-01
$3.24M
derived: sum of 2 quarters · filed 2019-05-09
$17.00M
derived: sum of 3 quarters · filed 2019-05-09
$38.66M
derived: sum of 4 quarters · filed 2019-05-09
2018-03-31$1.59M
10-Q · filed 2019-05-09
$15.35M
derived: sum of 2 quarters · filed 2019-05-09
$37.01M
derived: sum of 3 quarters · filed 2019-05-09
$54.16M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$13.76M
10-K · filed 2019-03-01
$35.42M
derived: sum of 2 quarters · filed 2019-03-01
$52.57M
derived: sum of 3 quarters · filed 2019-03-01
$64.83M
10-K · filed 2019-03-01
2017-09-30$21.66M
10-K · filed 2019-03-01
$38.81M
derived: sum of 2 quarters · filed 2019-03-01
$51.07M
10-Q · filed 2018-11-08
$63.97M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30$17.15M
10-K · filed 2019-03-01
$29.41M
10-Q · filed 2017-08-08
$42.31M
derived: sum of 3 quarters · filed 2019-03-01
$53.60M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31$12.26M
10-K · filed 2019-03-01
$25.16M
derived: sum of 2 quarters · filed 2019-03-01
$36.45M
derived: sum of 3 quarters · filed 2019-03-01
$46.45M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31$12.90M
10-K · filed 2018-03-01
$24.19M
derived: sum of 2 quarters · filed 2018-03-01
$34.20M
derived: sum of 3 quarters · filed 2018-03-01
$41.62M
10-K · filed 2019-03-01
2016-09-30$11.29M
10-K · filed 2018-03-01
$21.29M
derived: sum of 2 quarters · filed 2018-03-01
$28.71M
10-Q · filed 2017-11-09
$35.39M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30$10.00M
10-K · filed 2018-03-01
$17.42M
10-Q · filed 2017-08-08
$24.10M
derived: sum of 3 quarters · filed 2018-03-01
$27.36M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31$7.42M
10-K · filed 2018-03-01
$14.09M
derived: sum of 2 quarters · filed 2018-03-01
$17.35M
derived: sum of 3 quarters · filed 2018-03-01
$20.54M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31$6.67M
10-K · filed 2017-03-16
$9.93M
derived: sum of 2 quarters · filed 2017-03-16
$13.12M
derived: sum of 3 quarters · filed 2017-03-16
$13.51M
10-K · filed 2018-03-01
2015-09-30$3.26M
10-K · filed 2017-03-16
$6.45M
derived: sum of 2 quarters · filed 2017-03-16
$6.83M
10-Q · filed 2016-11-09
$7.01M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30$3.19M
10-K · filed 2017-03-16
$3.58M
10-Q · filed 2016-08-09
$3.75M
derived: sum of 3 quarters · filed 2017-03-16
$3.97M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31$388.00K
10-K · filed 2017-03-16
$568.00K
derived: sum of 2 quarters · filed 2017-03-16
$782.00K
derived: sum of 3 quarters · filed 2017-03-16
$827.00K
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31$180.00K
10-K · filed 2016-03-15
$394.00K
derived: sum of 2 quarters · filed 2016-03-15
$439.00K
derived: sum of 3 quarters · filed 2016-03-15
$539.00K
10-K · filed 2017-03-16
2014-09-30$214.00K
10-K · filed 2016-03-15
$259.00K
derived: sum of 2 quarters · filed 2016-03-15
$359.00K
10-Q · filed 2015-11-09
$528.00K
derived: sum of 4 quarters · filed 2016-03-15
2014-06-30$45.00K
10-K · filed 2016-03-15
$145.00K
10-Q · filed 2015-08-10
$314.00K
derived: sum of 3 quarters · filed 2016-03-15
$510.00K
derived: sum of 4 quarters · filed 2016-03-15
2014-03-31$100.00K
10-K · filed 2016-03-15
$269.00K
derived: sum of 2 quarters · filed 2016-03-15
$465.00K
derived: sum of 3 quarters · filed 2016-03-15
$605.00K
derived: sum of 4 quarters · filed 2016-03-15
2013-12-31$169.00K
10-K · filed 2015-03-16
$365.00K
derived: sum of 2 quarters · filed 2015-03-16
$505.00K
derived: sum of 3 quarters · filed 2015-03-16
$1.60M
10-K · filed 2016-03-15
2013-09-30$196.00K
10-K · filed 2015-03-16
$336.00K
derived: sum of 2 quarters · filed 2015-03-16
$1.43M
10-Q · filed 2014-11-10
$3.01M
derived: sum of 4 quarters · filed 2015-03-16
2013-06-30$140.00K
10-K · filed 2015-03-16
$1.24M
10-Q · filed 2014-08-11
$2.82M
derived: sum of 3 quarters · filed 2015-03-16
$4.24M
derived: sum of 4 quarters · filed 2015-03-16
2013-03-31$1.09M
10-K · filed 2015-03-16
$2.68M
derived: sum of 2 quarters · filed 2015-03-16
$4.09M
derived: sum of 3 quarters · filed 2015-03-16
$5.62M
derived: sum of 4 quarters · filed 2015-03-16
2012-12-31$1.58M
10-K · filed 2014-03-13
$3.00M
derived: sum of 2 quarters · filed 2014-03-13
$4.53M
derived: sum of 3 quarters · filed 2014-03-13
$6.02M
10-K · filed 2015-03-16
2012-09-30$1.42M
10-K · filed 2014-03-13
$2.94M
derived: sum of 2 quarters · filed 2014-03-13
$4.44M
10-Q · filed 2013-11-07
$5.58M
derived: sum of 4 quarters · filed 2014-03-13
2012-06-30$1.53M
10-K · filed 2014-03-13
$3.02M
10-Q · filed 2013-08-09
$4.17M
derived: sum of 3 quarters · filed 2014-03-13
$5.15M
derived: sum of 4 quarters · filed 2014-03-13
2012-03-31$1.50M
10-K · filed 2014-03-13
$2.64M
derived: sum of 2 quarters · filed 2014-03-13
$3.63M
derived: sum of 3 quarters · filed 2014-03-13
$4.78M
derived: sum of 4 quarters · filed 2014-03-13
2011-12-31$1.14M
10-K · filed 2013-03-18
$2.13M
derived: sum of 2 quarters · filed 2013-03-18
$3.29M
derived: sum of 3 quarters · filed 2013-03-18
$4.52M
10-K · filed 2014-03-13
2011-09-30$987.00K
10-K · filed 2013-03-18
$2.14M
derived: sum of 2 quarters · filed 2013-03-18
$3.38M
10-Q · filed 2012-11-09
$4.36M
derived: sum of 4 quarters · filed 2013-03-18
$10.32M
10-Q · filed 2011-11-08
2011-06-30$1.16M
10-K · filed 2013-03-18
$2.39M
10-Q · filed 2012-08-07
$3.37M
derived: sum of 3 quarters · filed 2013-03-18
$3.62M
derived: sum of 4 quarters · filed 2013-03-18
$9.34M
10-Q · filed 2011-08-09
2011-03-31$1.24M
10-K · filed 2013-03-18
$2.21M
derived: sum of 2 quarters · filed 2013-03-18
$2.47M
derived: sum of 3 quarters · filed 2013-03-18
$2.97M
derived: sum of 4 quarters · filed 2013-03-18
2010-12-31$976.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$1.23M
derived: sum of 2 quarters · filed 2013-03-18
$1.73M
derived: sum of 3 quarters · filed 2013-03-18
$2.10M
10-K · filed 2013-03-18
2010-09-30$254.00K
10-Q · filed 2011-11-08
$751.00K
derived: sum of 2 quarters · filed 2011-11-08
$1.13M
10-Q · filed 2011-11-08
2010-06-30$497.00K
10-Q · filed 2011-08-09
$875.00K
10-Q · filed 2011-08-09
2009-12-31$1.44M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Innoviva, Inc. (INVA)United States$1.493B4.62
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Kardigan, Inc. (KARD)United States$1.346B
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82